FDA Third Party Review Program: A 2026 Regulatory Guide

The FDA Third Party Review Program, formally known as the 3P510k program, is defined as a voluntary pathway that authorizes FDA-accredited Third Party Review Organizations to conduct primary reviews of eligible Class I and II medical device 510(k) submissions, with FDA retaining final clearance authority. Established under Section 523 of the Federal Food, Drug, and Cosmetic Act and administered by the FDA’s Center for Devices and Radiological Health (CDRH), this program gives regulatory professionals a faster alternative to the standard FDA review queue. Understanding what is FDA third party review program means for your submission strategy is critical in 2026, as updated guidance and evolving accreditation standards continue to reshape how manufacturers approach 510(k) clearance.

What is the FDA third party review program?

The 3P510k program authorizes FDA-accredited Third Party Review Organizations (3P510k ROs) to perform the primary technical review of qualifying 510(k) submissions. About 50% of 510(k) device types are eligible for this pathway. That figure means a significant portion of medical device manufacturers can access a faster review channel without bypassing FDA oversight.

The program is entirely voluntary. Manufacturers choose to engage a 3P510k RO, pay the reviewer’s fees directly, and submit their 510(k) to the third party rather than directly to FDA. FDA then receives the third party’s recommendation and typically issues a final clearance decision within 30 days. FDA does not charge a user fee for submissions processed through this pathway, though third-party fees apply.

FDA retains absolute final authority throughout the process. The third party’s role is to conduct a thorough technical review and issue a recommendation. FDA can accept that recommendation, request additional information, or conduct its own independent review. The program improves efficiency. It does not transfer decision-making power away from FDA.

What devices are eligible for third party review?

Eligibility is more specific than most regulatory professionals initially expect. A device qualifies for the 3P510k pathway only when all of the following conditions are met:

• The device is Class I or Class II under FDA classification.
• The device is not permanently implantable.
• The device is not life-supporting or life-sustaining.
• The device’s product code appears on FDA’s List of Devices for Third Party Review.
• At least one accredited 3P510k RO is currently authorized to review that specific product code.

The last two criteria are where many submissions run into trouble. A device can be Class II and still be ineligible if its product code is not on the FDA list, or if no accredited reviewer currently holds authorization for that code. FDA’s november 2024 final guidance reinforced the requirement to verify both conditions before initiating the third-party review process.

Regulatory professionals should treat eligibility verification as a two-step check. First, confirm the product code appears on the FDA list. Second, confirm that an active, accredited 3P510k RO is authorized for that code. Skipping either step wastes time and resources. The FDA list is updated periodically, so checking it close to your submission date is the only reliable approach.

Pro Tip: Cross-reference the FDA’s published list of accredited third-party reviewers against your device’s product code before engaging any reviewer. Authorization status can change, and a reviewer may be accredited but not authorized for your specific code.

How does FDA accredit and oversee third party reviewers?

FDA’s accreditation process for 3P510k ROs is structured around recognition, ongoing oversight, and the authority to suspend or withdraw recognition when standards are not met. Reviewers must comply with IMDRF standards, Good Regulatory Review Practices, and MDSAP. These are internationally recognized frameworks that set the baseline for review quality.

The accreditation process follows a clear sequence:

1. Application and recognition. An organization applies to FDA for recognition as a 3P510k RO. FDA evaluates the organization’s qualifications, quality systems, and device-specific expertise.
2. Core curriculum training. Recognized reviewers complete FDA’s established training curriculum, which includes device-specific courses designed to produce FDA-equivalent review quality.
3. Performance monitoring. FDA tracks published metrics for each accredited reviewer, including not substantially equivalent (NSE) rates and average hold rates. These metrics are publicly available and give sponsors a transparent basis for evaluating reviewer performance.
4. Suspension or withdrawal. FDA can suspend or withdraw recognition if a reviewer fails to maintain compliance or poses a threat to public health. This authority keeps the program’s quality standards enforceable.

Sponsor due diligence on reviewer selection is as critical as the accreditation system itself. An accredited reviewer is not automatically the right choice for your submission. Reviewing published performance metrics, verifying current authorization status, and assessing the reviewer’s experience with your device type are all necessary steps. Regulatory professionals working with international compliance frameworks will recognize the MDSAP requirement as a familiar quality benchmark.

Pro Tip: Request a reviewer’s NSE rate and average hold rate for your specific device category before signing an engagement agreement. FDA publishes this data, and a high NSE rate for your device type is a clear warning sign.

What are the benefits and challenges of the 3P510k program?

The primary benefit of the third party review FDA pathway is speed. FDA typically issues final clearance within 30 days of receiving the third party’s recommendation. That timeline is significantly shorter than standard FDA review queues, which gives manufacturers a meaningful time-to-market advantage for eligible devices.

The program also delivers risk management value that goes beyond speed. Predictable timelines allow regulatory teams to plan product launches, manufacturing ramp-ups, and commercial activities with greater confidence. Reducing FDA’s internal review burden also reduces the risk of your submission sitting in a queue during periods of high FDA workload.

The 3P510k program is not a cheaper review path. It is a faster and more predictable one. Sponsors who enter the program expecting to save money are often surprised by third-party fees. Sponsors who enter it expecting a more controlled timeline are rarely disappointed.

The challenges are real and require active management:

• Conflict of interest (COI) failures are the most common cause of delays. A reviewer with any prior involvement in consulting, testing, or ownership related to your device or its competitors must be disqualified. COI screening beyond FDA’s minimum requirements is the standard of care.
• Eligibility misidentification causes wasted effort. Assuming a Class II device is automatically eligible without verifying the product code and active reviewer authorization is a recurring mistake.
• Cost expectations need calibration. No FDA user fee applies, but third-party fees offset much of that saving. The value proposition is speed and predictability, not cost reduction.
• FDA re-review potential must be factored into timelines. Even a positive third-party recommendation does not eliminate the possibility of FDA requesting additional information.

How to select and work with a third party review organization

Selecting the right 3P510k RO requires a structured screening process. Regulatory professionals who treat this selection with the same rigor applied to clinical research organization selection consistently achieve better outcomes.

The following comparison covers the key evaluation criteria for 3P510k RO selection:

Early interaction consultations between sponsors and third-party reviewers are underutilized across the industry. FDA’s november 2024 final guidance specifically recommends these consultations to align on testing requirements and submission content before formal review begins. Sponsors who skip this step frequently encounter holds that could have been resolved in a pre-submission meeting.

Verifying product code authorization at the reviewer level, not just the accreditation level, is non-negotiable. Some accredited organizations hold authorization for a narrow set of product codes. Submitting to a reviewer who lacks authorization for your code results in rejection and lost time. Build a timeline buffer of at least 30 additional days beyond the third-party review period to account for potential FDA re-review. For guidance on building a complete 510(k) submission strategy, that buffer is a standard planning assumption.

Pro Tip: Treat the early interaction consultation as a dry run for your submission. Bring your testing data, predicate device rationale, and any open questions. Reviewers who identify gaps at this stage save you weeks of holds during formal review.

How does FDA maintain final authority after third party review?

FDA’s final authority over 510(k) clearance is absolute and unchanged by the third-party review process. The third party issues a recommendation. FDA makes the decision. That distinction matters for how regulatory professionals plan their submissions and manage stakeholder expectations.

FDA’s post-review actions fall into three categories:

• Acceptance of the recommendation. FDA reviews the third party’s report and issues clearance, typically within 30 days. This is the expected outcome for well-prepared submissions with a positive recommendation.
• Request for additional information. FDA may identify gaps in the submission or the third party’s review and request supplemental data. This extends the clearance timeline and requires a prepared response strategy.
• Independent re-review. FDA retains the authority to conduct its own full review of any submission, regardless of the third party’s recommendation. Third party reviews improve efficiency but do not guarantee clearance without FDA involvement.

The strategic implication is clear. Preparing a 510(k) submission for third-party review requires the same rigor as preparing one for direct FDA submission. Shortcuts in technical documentation, predicate device analysis, or performance testing create vulnerabilities that FDA will identify, even after a positive third-party recommendation. Regulatory professionals who build their medical device regulatory strategy around the assumption of FDA follow-up are consistently better positioned than those who treat third-party clearance as a foregone conclusion.

Key Takeaways

The FDA Third Party Review Program accelerates 510(k) clearance for eligible Class I and II devices, but its value depends entirely on rigorous eligibility verification, careful reviewer selection, and thorough submission preparation.

The part of the 3P510k program most teams get wrong

After working with regulatory teams across medical device manufacturers, the pattern I see most often is not a failure to understand the program. It is a failure to treat reviewer selection with the seriousness it deserves.

Teams spend months preparing a 510(k) submission and then spend two days selecting a third-party reviewer. That ratio is backwards. The reviewer you choose determines your timeline, your hold rate, and your COI exposure. A poorly selected reviewer with a high NSE rate for your device category can turn a 30-day clearance into a six-month ordeal.

The other mistake I see consistently is skipping the early interaction consultation. Regulatory professionals often view it as an optional courtesy. It is not. It is the single most effective tool for reducing review holds, and it costs far less time than responding to a formal additional information request mid-review.

My honest recommendation: integrate 3P510k eligibility assessment into your regulatory strategy at the product development stage, not at the submission stage. Knowing early that your device qualifies for this pathway changes how you plan testing, timelines, and commercial launch. That early awareness is where the real time-to-market advantage is captured. For teams building that kind of forward-looking FDA compliance strategy, the 3P510k program belongs in the conversation from day one.

— Mike

How Jjccgroup supports your 3P510k submission strategy

Navigating the FDA Third Party Review Program requires more than reading guidance documents. It requires knowing which reviewers perform well for your device category, how to structure your submission to minimize holds, and how to plan for FDA’s post-review involvement.

Jjccgroup brings over 30 years of FDA compliance expertise to medical device regulatory submissions. The team supports manufacturers through eligibility assessment, reviewer selection, COI screening, and submission preparation, giving you a clear path from development to clearance. Whether you are approaching your first 510(k) or refining a multi-product regulatory strategy, Jjccgroup’s FDA compliance services are built for the complexity you face. Connect with the team to discuss your device’s eligibility and build a submission plan that accounts for every stage of the review process.

FAQ

What is the FDA Third Party Review Program?

The FDA Third Party Review Program is a voluntary pathway that allows FDA-accredited organizations to conduct primary reviews of eligible Class I and II medical device 510(k) submissions, with FDA issuing final clearance typically within 30 days of receiving the reviewer’s recommendation.

Which devices qualify for third party review FDA?

A device qualifies if it is Class I or II, not permanently implantable or life-sustaining, and its product code appears on FDA’s published list with at least one accredited reviewer currently authorized for that code.

Are there FDA user fees for the 3P510k program?

No FDA user fee applies to submissions processed through the third-party review pathway. Manufacturers pay the accredited third-party reviewer directly, and those fees vary by organization and device type.

How does FDA maintain oversight of third party reviewers?

FDA publishes performance metrics including NSE rates and hold rates for each accredited reviewer, and retains authority to suspend or withdraw recognition for non-compliance or public health concerns.

Can FDA reject a device after a positive third-party recommendation?

Yes. FDA retains final clearance authority and may request additional information or conduct its own review regardless of the third party’s recommendation, so sponsors should plan for this possibility in every regulatory timeline.

Recommended

• Why Pharma Needs Third Party Audits: 2026 Guide
• The Role of FDA in Pharma: 2026 Regulatory Guide